Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1123

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Indacaterol 150 µg
DRUG: Salmeterol 50 µg
DRUG: Placebo to indacaterol
DRUG: Placebo to salmeterol

Sponsor

Novartis Pharmaceuticals